MedTrace Logo

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

NCT06644625 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1665

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Conditions

  • Multiple Myeloma
  • Multiple Myeloma Progression
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • Plasma Cell Disorders

Interventions

OTHER

Blood draw for the laboratory assessment

Screening blood sample collection to test for MGUS

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Manisha Bhutani, MD · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2035-01-31
Completion
2035-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644625 on ClinicalTrials.gov